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Hydrotropy refers to increasing the water solubility of otherwise poorly soluble
compound by the presence of small organic molecules. While it can certainly increase
the apparent solubility of a lipophilic drug, the effect of hydrotropy on the drugs’
permeation through the intestinal membrane has not been studied. The purpose of
this work was to investigate the solubility–permeability interplay when using hydrotropic
drug solubilization. The concentration-dependent effects of the commonly used
hydrotropes urea and nicotinamide, on the solubility and the permeability of the lipophilic
antiepileptic drug carbamazepine were studied. Then, the solubility–permeability
interplay was mathematically modeled, and was compared to the experimental data.
Both hydrotropes allowed significant concentration-dependent carbamazepine solubility
increase (up to∼30-fold). A concomitant permeability decrease was evident both in vitro
and in vivo (∼17-fold for nicotinamide and ∼9-fold for urea), revealing a solubility–
permeability tradeoff when using hydrotropic drug solubilization. A relatively simplified
simulation approach based on proportional opposite correlation between the solubility
increase and the permeability decrease at a given hydrotrope concentration allowed
excellent prediction of the overall solubility–permeability tradeoff. In conclusion, when
using hydrotropic drug solubilization it is prudent to not focus solely on solubility, but to
account for the permeability as well; achieving optimal solubility–permeability balance
may promote the overall goal of the formulation to maximize oral drug exposure.
Keywords: drug absorption, hydrotropic solubilization, intestinal permeability, oral drug delivery, solubility
INTRODUCTION
In recent years, modern drug discovery efforts have been producing more and more lipophilic
drug candidates, and according to some estimates more than 50% of new drug entities exhibit
poor water solubility (Lipinski et al., 2001; Dahan et al., 2013b; Pham-The et al., 2013; Wolk
et al., 2014). According to the biopharmaceutics classification system (BCS; Amidon et al.,
1995), the oral absorption of these drugs may be limited by their solubility/dissolution in the
aqueous gastrointestinal (GI) milieu (Lobenberg and Amidon, 2000; Martinez and Amidon, 2002;
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Dahan et al., 2009). The use of different solubility-enabling
formulations is a very common practice in tackling solubility
limitations, however, in recent years, it was reported that care
should be taken when using these formulations; in some cases
it was evident that the increased solubility afforded by the
formulations in accompanied by a parallel decreased intestinal
permeability (Dahan and Miller, 2012; Beig et al., 2015b).
Since solubility and permeability together were identified as
the key factors dominating oral drug absorption (Lennernas,
1998; Lennernäs and Abrahamsson, 2005; Dahan et al., 2010a,
2012), this tradeoff may jeopardize the ability of a given
formulation to improve the overall absorption. For instance, the
use of cyclodextrin-based formulations was associated with such
solubility–permeability tradeoff (Dahan et al., 2010b; Beig et al.,
2013a, 2015a). Likewise, surfactants (Miller et al., 2011; Hens
et al., 2015) and cosolvent-based delivery systems resulted in
permeability decrease concomitantly to the solubility increase
(Beig et al., 2012; Miller et al., 2012b). On the other hand, no such
tradeoff was observed with amorphous solid dispersions (ASD)
irrespective of the supersaturation level attained (Miller et al.,
2012a; Dahan et al., 2013a, 2016). This fundamental difference
between different solubilization methods and ASD formulations
represent a significant advantage of the latter, as ASD may
increase the drug flux across the intestinal barrier (which is the
product of solubility times permeability) more easily than the
above mentioned solubilization techniques.
Hydrotropy is an emerging powerful drug solubilization
strategy, which has been shown to significantly improve the
solubility of many drugs (Booth et al., 2012). Hydrotropy refers
to the process by which a large amount of solute (the hydrotrope)
enhances the solubility of another compound (the drug), by
a mechanism that is not yet fully understood (Shimizu et al.,
2013). Hydrotropic agents are typically characterized by an
amphiphilic molecular structure, however, they are distinguished
from surfactants because their hydrophobicity is not sufficient to
produce well organized self-associated aggregates such as micelles
(Hodgdon and Kaler, 2007; Eastoe et al., 2011; Booth et al., 2015).
In fact, self-aggregation of the hydrotrope molecules hampers the
hydrotropy capacity (Booth et al., 2012; Shimizu et al., 2013).
Hydrotropic drug solubilization is also mechanistically different
from cosolvency. For instance, while cosolvents enhance drug
solubility by minimizing the polarity gap between the solvent
and the drug, it was reported that hydrotropes preferentially
concentrate nearby the drug molecules (da Silva et al., 1999).
It is likely that the combination of a number of mechanisms
responsible for hydrotropic drug solubilization, including the
depression of water activity and drug-hydrotrope interactions
(Shimizu et al., 2013). Overall, it emerges that hydrotropy is a
distinctive standalone drug solubilization technique, which may
dramatically increase the apparent solubility of drugs (Agrawal
et al., 2004; Kim et al., 2010, 2011).
Hydrotropes are frequently anionic aromatic (e.g., salicylate,
benzoate) or non-aromatic compounds (e.g., citrate), but can also
be neutral (e.g., urea; Herbig and Evers, 2013). Urea is widely used
as a hydrotropic agent, as it was shown to enhance the aqueous
solubility of many lipophilic drugs including diclofenac (250-
fold), hydrochlorothiazide (74-fold), and many others (Coffman
and Kildsig, 1996a,b). Urea constitutes a near-ideal mixture
with water; in contrast to several other hydrotropes, urea
exhibits weak self-association in water, and since hydrotrope
self-association reduces the solubilization capacity, urea exhibits
very minor loss of solubilization efficiency (Booth et al., 2012,
2015). Nicotinamide, the product of nicotinic acid (niacin) in vivo
conversion, is another effective and commonly used hydrotrope,
which has been demonstrated to solubilize a wide variety of
lipophilic drugs (Sanghvi et al., 2007; Cui et al., 2010; Booth et al.,
2015).
The primary purpose of this work was to investigate the
solubility–permeability interplay when using hydrotropic
drug solubilization; revealing whether hydrotropy generates
solubility–permeability tradeoff (similarly to cyclodextrins,
surfactants and cosolvents), or it affords solubility increase
without hampering the permeability (similarly to ASD
formulations), is critical to the overall use of this technique. We
have selected the two commonly used hydrotropes urea and
nicotinamide, and studied their concentration-dependent effects
on the solubility, the in vitro and in vivo permeability, and the
solubility–permeability interplay, of the lipophilic antiepileptic
drug carbamazepine. Then, we made an effort to allow a
priori computational prediction of the solubility–permeability
interplay when using hydrotropic drug solubilization, to facilitate
the development of an optimized formulation. Overall, this work
aimed to reveal significant mechanistic insights regarding the use
of hydrotropic solubilization in oral delivery of lipophilic drugs.
MATERIALS AND METHODS
Materials
Urea, nicotinamide, carbamazepine, and MES buffer were
purchased from Sigma Chemical Co. (St. Louis, MO, USA).
Potassium chloride and sodium chloride were obtained from
Fisher Scientific Inc. (Pittsburgh, PA, USA). Acetonitrile,
methanol and water (Merck KGaA, Darmstadt, Germany) were
UPLC grade. All other chemicals were of analytical reagent grade.
Solubility
Carbamazepine solubility was measured at increasing
concentrations (0–40% w/v) of hydrotrope (urea vs.
nicotinamide) in 10 mM MES buffer, pH 6.5, at room
temperature (25◦C) and at 37◦C as described previously
(Fairstein et al., 2013; Zur et al., 2014a). Briefly, excess of
drug powder was incubated with different urea/nicotinamide
solutions (0–40% w/v) for 24–48 h, followed by centrifugation,
supernatant withdrawal, filtration, and UPLC analysis for drug
content.
In vitro Parallel Artificial Membrane
Permeability Assay (PAMPA) Permeability
Parallel artificial membrane permeability assay (PAMPA)
was carried out using a method previously reported (Sun
et al., 2009; Zur et al., 2014b). In brief, carbamazepine
solutions were prepared with different levels (0–40% w/v)
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of hydrotrope (urea vs. nicotinamide) in MES buffer pH 6.5.
Carbamazepine concentrations in the different urea levels were
calculated to achieve 75% saturation in all experimental groups.
PAMPA experiments were carried out in 96-well MultiScreen-
Permeability filter plates with 0.3 cm2 polycarbonate filter
support (0.45 mm). The filter supports in each well were first
filled with 15 µL of a 5% solution (v/v) of hexadecane in hexane.
After evaporation of the hexane (60 min), the carbamazepine-
hydrotrope solutions were placed in each donor well, and the
receiver wells were filled with blank MES buffer solution. The
donor plate was then set upon the receiver plate, and was
incubated with shaking at room temperature (25◦C). Samples
from the receiver wells were collected every 30 min over 2.5 h
and were assayed for drug content by UPLC.
The in vitro permeability (Papp; cm/sec) of carbamazepine
was calculated from the steady-state drug accumulation in the
receiver well (dQ/dt) according to the following equation:
Papp = dQ
/
dt
AC0
where A is the membrane surface area available for permeation,
and C0 is carbamazepine’s initial concentration in the donor well.
In vivo Permeability Studies in Rats
All animal studies protocols were approved by the Animal Use
and Care Committee of Ben-Gurion University of the Negev
(Protocol IL-08-01-2015). Animals were housed and handled
according to Ben-Gurion University of the Negev Unit for
Laboratory Animal Medicine Guidelines. Male 300–330 g Wistar
rats (Harlan, Israel) were used for these studies.
The single-pass intestinal perfusion studies were carried out
as previously described (Varghese Gupta et al., 2011; Gupta
et al., 2013; Lozoya-Agullo et al., 2015). Briefly, carbamazepine
solutions were prepared with hydrotrope (0, 10, 20, and
30%, urea vs. nicotinamide) in 10 mM MES buffer (pH 6.5).
Drug concentrations in the different urea/nicotinamide levels
were calculated according to the solubility data at 37◦C to
achieve 75% saturation in all experimental groups. A 10 cm
segment of the jejunum was cannulated at both ends, and the
carbamazepine-hydrotrope solution was perfused through this
intestinal segment. Comparison of the inlet vs. the outlet drug
concentrations was used to calculate the permeability (Peff),
according to the following equation (Zur et al., 2015):
Peff =
−Q ln
(
C
′
out
/
C
′
in
)
2piRL
where Q is the perfusion flow rate (0.2 mL/min), C
′
out/C
′
in is the
ratio of outlet vs. inlet carbamazepine concentrations adjusted to
water flux, R is the intestinal radius (set to 0.2 cm), and L is the
length of the perfused jejunal segment, accurately measured at the
end of the experiment. Stability of the drug in the intestinal lumen
was evaluated to eliminate the option of drug disappearance that
is not attributable to absorption.
Ultra-Performance Liquid
Chromatography (UPLC)
Ultra-performance liquid chromatography (UPLC) experiments
were performed on a Waters (Milford, MA, USA) Acquity UPLC
H-Class system equipped with photodiode array (PDA) detector
and Empower software, as previously described in detail (Beig
and Dahan, 2014). The mobile phase consisted of 30:70 going
to 70:30 (v/v) 0.1% TFA in water: 0.1% TFA in acetonitrile over
8 min, that was pumped at a flow rate of 0.5 mL/min. Injection
volumes for all UPLC analyses ranged from 5 to 50 µL, and the
detection wavelength was 285 nm.
Statistical Analysis
Solubility and in vivo permeability studies were n= 5 and in vitro
PAMPA permeability experiments were n= 6. Data are expressed
as mean ± standard deviation (SD). To determine statistically
significant differences among the experimental groups, the
non-parametric Kruskal–Wallis test was used for multiple
comparisons, and the non-parametric Mann–Whitney U test for
two-group comparison where appropriate. A p-value lower than
0.05 was considered significant.
RESULTS
Carbamazepine-Hydrotrope Solubility
Studies
Carbamazepine solubility at room temperature (25◦C) and at
37◦C as a function of hydrotrope concentration is presented in
Figure 1. Three main findings can be readily seen in Figure 1:
(1) hydrotropic solubilization of carbamazepine, using either
urea or nicotinamide, is a powerful solubilization method that
can dramatically increase the drugs’ apparent solubility; (2)
while carbamazepine’s solubility in the absence of any excipient
is temperature-dependent (the drug’s solubility is more than
doubled at 37◦C), the two hydrotropes react very differently to
temperature variation: it can be seen that the ability of urea
to increase carbamazepine solubility is temperature-dependent,
while nicotinamide is not; and (3) closer analysis of the effect
of urea reveals that while at room temperature the increased
solubility appears to be linear as urea level increases, at 37◦C
carbamazepine shows biphasic solubility trend, with higher slope
at hydrotrope (urea) levels above 10% w/v. Analogous findings
were recently reported for the hydrotropic solubilization of the
lipophilic drugs griseofulvin and estrone (Sanghvi et al., 2007).
The effect of nicotinamide appears to be linear at all hydrotrope
concentrations studied.
The Effect of Hydrotrope on
Carbamazepine In vitro Permeability
Carbamazepine in vitro permeability as a function of increasing
levels of urea (black bars) or nicotinamide (white bars) is
presented in Figure 2. It can be seen that with both hydrotropes
the drug’s apparent permeability decreased significantly with
increasing hydrotrope levels (and increased apparent solubility)
in a concentration- dependent manner. This result indicates that
Frontiers in Pharmacology | www.frontiersin.org 3 October 2016 | Volume 7 | Article 379
fphar-07-00379 October 22, 2016 Time: 14:37 # 4
Beig et al. Hydrotropic Solubilization and the Solubility-Permeability Interplay
FIGURE 1 | Apparent solubility (µg/mL) of carbamazepine as a function of increasing urea (left panel) or nicotinamide (right panel) levels at 37◦C (•)
and at 25◦C (room temperature; o). Data are presented as mean ± SD; n = 5.
a tradeoff between solubility increase and permeability decrease
exists when using hydrotropic drug solubilization, which means
that every solubility gain is accompanied by a concomitant
permeability loss.
The Effect of Hydrotrope on
Carbamazepine In vivo Permeability
The rat intestinal permeability of carbamazepine from drug
solutions containing increasing levels of nicotinamide (left panel)
and urea (right panel) is presented in Figure 3. Similarly to
the in vitro permeability results, significantly decreased effective
in vivo carbamazepine permeability was found with increasing
hydrotrope levels (and increased apparent solubility). Once more,
FIGURE 2 | Experimental apparent in vitro PAMPA permeability
(cm/sec) of carbamazepine as a function of increasing levels of urea
(black bars) or nicotinamide (white bars). Data are presented as
mean ± SD; n = 6.
it was revealed that the in vivo solubility–permeability interplay
when using hydrotropic drug solubilization has the nature of
a tradeoff, confirming that the increased apparent solubility via
hydrotropy comes with a price tag of simultaneous decreased
intestinal permeability.
Solubility–Permeability Interplay When
Using Hydrotropy
To fully capture the simultaneous effects of hydrotropic drug
solubilization on the solubility and the permeability, the
correlation between the nicotinamide/urea level and the resulted
carbamazepine apparent solubility–permeability were modeled.
In both cases, the decreased permeability was a mirror-image
of the increased solubility of carbamazepine as a function of
hydrotrope concentration. This point encouraged us to estimate
carbamazepine’s membrane permeability at a given hydrotrope
level from the proportional increase in the apparent solubility
of the drug. Basically, we plotted the theoretical permeability
decrease as a function of hydrotrope concentration, according
to the solubility enhancement afforded by this hydrotrope level,
according to the following equation:
Pm = Pm(o)Saq(o)Saq
where Pm, the apparent intestinal membrane permeability at
a given hydrotrope level is equal to the intrinsic membrane
permeability of the drug in the absence of hydrotrope (Pm(o))
adjusted to the ratio between the intrinsic solubility, that is,
carbamazepine’s solubility in the absence of hydrotrope (Saq(o))
to the apparent solubility obtained at the same hydrotrope
level (Saq). The resulted theoretical (vs. experimental) solubility–
permeability interplay as a function of increasing nicotinamide
(left panel) or urea (right panel) concentrations is illustrated
in Figure 4. The agreement between the calculated and the
experimental values is noticeably confirmed; this figure clearly
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FIGURE 3 | Carbamazepine in vivo permeability as a function of increasing nicotinamide (left panel) or urea levels (right panel) in the single-pass
intestinal rat perfusion model. Data are presented as mean ± SD; n = 5.
FIGURE 4 | Experimental (circles) vs. theoretical (lines) solubility (blue) and in vivo permeability (red) of carbamazepine as a function of increasing
nicotinamide (left panel) or urea (right panel) levels in the single-pass intestinal perfusion model, illustrating the solubility–permeability tradeoff when
using hydrotropic drug solubilization.
demonstrates the opposing concomitant effects of hydrotropic
drug solubilization on the drug’s apparent solubility and intestinal
permeability.
DISCUSSION
Low water solubility is a major concern in todays’
biopharmaceutics. While hydrotropy may assist to increase
the apparent solubility of a lipophilic drug, the effect of this
solubilization method on the drug’s permeability has not
been investigated yet. The focus of this work was to evaluate
the solubility–permeability interplay when using hydrotropy
in solubility-enabling formulations for lipophilic drugs. It
was revealed that, similarly to cyclodextrins, surfactants,
and cosolvents, and unlike ASD formulations, hydrotropy is
associated with a solubility–permeability tradeoff phenomenon,
which means that the solubility gain afforded by the formulation
has the “price” of concomitant permeability loss. This finding
significantly affects the use of hydrotropic drug solubilization, as
it is now clear that the solubility–permeability interplay cannot
be ignored throughout the formulation development process;
it is not enough to allow the highest solubility possible, rather,
the optimal solubility–permeability balance should be aimed in
order to maximize the overall oral drug absorption.
In our previous reports we have detected a fundamental
mechanistic reason that governs the solubility–permeability
interplay nature; while cyclodextrins-, surfactants-, and
cosolvents-based solubilization modify the equilibrium aqueous
solubility of the drug, supersaturation achieved by ASD
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formulation is a non-equilibrium/kinetic increase of the drug’s
apparent solubility (Miller et al., 2012a; Dahan et al., 2013a).
Since the equilibrium aqueous solubility of the drug controls its
membrane/aqueous partition coefficient, which in turn controls
the drug’s (passive) intestinal permeability, increased equilibrium
solubility inherently decreases the drug’s partitioning and the
overall permeability, resulting in the solubility–permeability
tradeoff obtained with cyclodextrins, surfactants and cosolvents
(Miller and Dahan, 2012; Beig et al., 2013b). On the other
hand, ASD formulations that allow to achieve and maintain
supersaturation which is a non-equilibrium increase of the drugs’
apparent solubility, do not affect neither the drug’s partitioning
not its permeability, circumventing the complication of the
solubility–permeability tradeoff (Dahan et al., 2016). This
analysis highlights that the data presented in this article
unequivocally indicate that the mechanism for hydrotropic drug
solubilization involves modification of the equilibrium aqueous
solubility of the drug. Since the exact mechanism of hydrotropy
is not yet fully understood, this finding may contribute to the
overall understanding of hydrotropic drug solubilization.
The main structural characteristic of hydrotropes includes
hydrocarbon fragment and an ionic moiety. This amphiphilic
molecular structure is assumed to play a role in hydrotropic
drug solubilization (Li et al., 2015; Patil et al., 2015). The
hydrotrope molecules are assumed to self-aggregate by a stacking
mechanism, in a manner closely related to surfactants (Bauduin
et al., 2005). However, the effect of hydrotropy on the surface
tension and other parameters was reported to significantly differ
from surfactants, indicating that hydrotrope self-aggregation may
not be as central as with micellar solubilization (Balasubramanian
et al., 1989; Horváth-Szabó et al., 2001). Changing the solute-
water interaction by changing the solvent’s ability to join structure
formation through intermolecular hydrogen bonding was also
suggested as a potential mechanism for hydrotropy (Coffman
and Kildsig, 1996a,b), however, recent enthalpy calculations
have doubted the role of this mechanism as well (Shimizu
et al., 2013). Another proposed mechanism includes hydrotrope
molecules fit around the solute, turning its solvation more
susceptible (Hussain et al., 1993; da Silva et al., 1999), although
the drug and the hydrotrope may not have a direct mutual
attraction, rather, they interact to minimize their contact with
water (Sanghvi et al., 2007). Overall, it is likely that the
combination of several mechanisms together, rather than one
central process, is responsible for the powerful hydrotropic drug
solubilization. The biphasic solubility enhancement revealed with
urea (Figure 1, left) also supports the idea of a combination of
different mechanisms; it is likely that at lower urea concentration
one mechanism is active, and at a critical hydrotrope level
(10% w/w in our case) an additional mechanism kicks in and
enhances the solubilization capacity, resulting in the biphasic
trend. Hydrotropic solubilization using nicotinamide showed no
such biphasic effect (Figure 1, right panel), suggesting that the
different dominant mechanisms of hydrotropy may differ from
one hydrotrope to another; similar slopes were obtained for the
hydrotropic solubilization by urea above 10% at 37◦C and by
nicotinamide at all conditions, suggesting similar predominant
solubilization mechanisms for these two hydrotropes under
certain conditions, but not necessarily under other conditions
(e.g., at room temperature or below 10% for urea). This point is
further highlighted by the very different reaction to temperature
of the two studied hydrotropes: while the ability of urea to
increase carbamazepine solubility had a strong temperature-
dependency, it was revealed that nicotinamide can produce its
full 37◦C solubilization capacity already at room temperature.
Revealing that hydrotropy influences the drugs’ equilibrium
solubility may also aid to elucidate the underlying mechanism(s)
of hydrotropy.
An excellent agreement was achieved between the
experimental permeability data and the predicted values,
both in vitro and in vivo (Figure 4), although a relatively
simplified prediction approach was taken. We have shown
before that in cases where the unstirred water layer (UWL)
adjacent to the intestinal wall plays a significant role as an
absorption barrier for lipophilic drugs, this simplified approach
may not be sufficient to allow this level of prediction, and a
more complicated quasi-equilibrium transport analysis may be
needed (Dahan et al., 2010b; Miller et al., 2011, 2012b). For
carbamazepine, we have shown previously that the UWL does
not act as a significant permeation barrier (Beig et al., 2012),
and hence the simplified approach presented in the paper,
that involves a proportional opposite correlation between the
solubility increase and the permeability decrease at a given
hydrotrope concentration, allowed excellent prediction of the
overall solubility–permeability interplay (Figure 4).
CONCLUSION
Hydrotrope-based solubility-enabling formulation can result
in significant water solubility increase, but at the same time
may cause intestinal permeation decrease. Hence, when using
hydrotropic drug solubilization it is prudent to not focus solely
on the solubility, but to account for the permeability as well.
Achieving optimal solubility–permeability balance may promote
the overall goal of the formulation to maximize drug exposure
following oral administration.
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